IPSA (Industrial Problem Solving Ability )

Slides:



Advertisements
Similar presentations
 AUTHOR- Musiba Baliruno Denis, B.pharm (MUST) SUPERVISORS ;  Prof. K.A.M. Kuria, PhD - Department of Pharmaceutics and Pharmacy Practice, University.
Advertisements

Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Training Workshop on Pharmaceutical Development.
2-5. Formulation Development Issues: Solid Orals Satish Mallya January, 2011.
By Timina Olive Kayaviri Supervisor : Dr. Amugune
Methods of tablet manufacturing
Abwova Veronica Vugutsa B. Pharm
TABLETS a mixture of powders compacted to form a single, rigid body most common dosage form possess a number of advantages B. AmsdenCHEE 440.
World Health Organization
Physical chemical and pharmaceutical-technological properties of powder and granules and their impact on the technology of solid dosage forms. Tablets.
Module 1, Part 3: Process validation Slide 1 of 22 © WHO – EDM – 12/2001 Validation Part 3: Process validation Supplementary Training Modules on Good Manufacturing.
PHARMACEUTICS- IV (PHT 414 ) Dr. Shahid Jamil SALMAN BIN ABDUL AZIZ UNIVERSITY COLLEGE OF PHARMACY L /9/2015 Factors Affecting Drug Absorption (Dosage.
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
Quality control Lecture 1.
Novel Multifunctional Excipients by Co-processing with Mg-Silicate Dr. Faisal Al-Akayleh Faculty of Pharmacy, Petra University.
Formulation factors By Dr. A. S. Adebayo.
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
Formulation, Characterization of Pellets of Duloxetine Hydrochloride by Extrusion and Spheronization Prof. V. R. Sinha University Institute of Pharmaceutical.
Introduction What is a Biowaiver?
Liquisolid drug delivery system
GRANULATION DR. MOHAMMAD KHALID ANWER Assistant Professor 2/25/20161 COLLEGE OF PHARMACY, PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY.
Tablet Granulation. Introduction  Granulation is the process in which primary powder particles are made to adhere to form larger, multi particle entities.
Quality control Lecture 1.
MICROMERITICS. Micromeritics: Definition: It is the science and technology of small particles. *The unit of particle size used is the micrometer,( μm),
Milling Is the reduction in the size mass by conversion of the large solid unit mass into smaller one by mechanical process. This needs energy.
Methods of tablet manufacturing
Tablets design and manufacture
Faculty of Pharmacy and Medical Sciences Al-Ahliyya Amman University
Physical Testing 1.Solutions 2.Disperse systems 3.Aerosols 4.Powders 5.Tablets 6.Sustained release products 7.Coated tablets 8.Hard & soft shell capsules.
- Pharmaceutical Equivalence Study
Results and Discussion
Problems associated with the manufacturing of tablets
Introduction What is a Biowaiver?
ASSESSMENT OF THE IMPACT OF HUMIDITY ON STABILITY OF APOTRIAVIR TABLETS AND ITS IMPLICATION IN BETTER TASTE RELEASE TRACPlus 2010 KIGALI, November 11,
Enabling direct compaction at high drug loading via dry coating of APIs: Towards a predictive framework Presenter(s): Kuriakose T. Kunnath, NJIT Research.
Gastrointestinal Absorption: Role of the Dosage Form
ABSTRACT Influence of Different Content of Lactose on the Release of Diclofenac Sodium Formulated in Controlled Release Matrix Tablets Containing.
Biopharmaceutics of modified release drug products
Wet Granulation.
Evaluation of tablet Lab 5.
Evaluation of tablet Lab 5.
TIMERx Oral Controlled-Release Drug Delivery System
Biopharmaceutic Considerations in Drug Product Design
Tablets design and manufacture
HHM 5014 NUTRACEUTICAL FORMULATION TECHNOLOGY
Group members: Firdaus | Sofia | Nurainiza | Hafizah
Factors Affecting Drug Absorption (Dosage form factor)
Disintegration test & Dissolution test (official test)
Quality control Lecture 1.
Milling Lab-6-.
Quality Control Requirement
J.Preethi*, P. Madhu, K. Arshad Ahmed Khan.
Lab -7- Capsules.
Tablet Dosage Form Lab 1.
Drug Delivery Systems Pharmaceutical technology Petra University.
LAB.2 Tablet Production Methods
Lab 3 Industrial pharmacy
Wet Granulation.
Lab -7- Capsules.
INTRODUCTION TO INDUSTRIAL PHARMACY
Aram I. Ibrahim University of sulaimani College of pharmacy
Pediatric Formulation Development - A quality perspective
Tablets Lecturer: dr. Asmaa abdelaziz Mohamed Faculty of pharamcay
Quality control Lecture 1.
Evaluation of tablet Lab 5.
Evaluation of tablet dosage form 5) dissolution
RingCap Technology Mrs. Maria Saifee Associate Professor,
Formulation factors By Dr. A. S. Adebayo.
University of sulaimani
Milling Lab-6-.
Tablets.
Presentation transcript:

IPSA (Industrial Problem Solving Ability ) PROBLEM: F-5 Prepare a manufacturing process for GLICLAZIDE SR-30 mg describing all the formulation and process parameters in detail TEAM NO : 23

CONTENTS: INTRODUCTION MANUFACURING PROCESS FLOW CHART INGREDIENT USED QUALITY TARGET PRODUCT PROFILE(QTPP) PROCESS PARAMETER

Introduction to Gliclzide CATEGORY: It is a sulphonylureas USE: antidiabetic (in NIDDM) HALF LIFE: 10.4 h (Duration of action is 10-24 h) BCS CLASS: class II DOSE: 40-320 mg (in two divided dose) 30 & 60 mg(for MR)

Introduction to Sustain Release They release a drug at a predetermined rate in order to maintain a constant drug concentration for a specific period of time with minimum side effects Minimize dosing frequency Minimizes fluctuations in serum drug levels For a drug having narrow therapeutic index To achieve zero order release rate of drug Patients compliance

MANUFACURING PROCESS FLOW Preformulation Study Manufacturing Of Tablets Drug Release Study Stability Study

Stability (With all excipients to be used) Preformulation Study Profile Component Method Criteria Flow Property Angle of repose: Inversly prop. Carr’s index: inversly prop, Hausner ratio, <30 Ф Solubility In Water 1-10mg/ml Melting point Capillary melting Hot stage microscopy DSC Stability (With all excipients to be used) FTIR Spectroscopy Must be Compatible Assay UV (227 nm) 95-105%

Solubility Enhancement of GLICLAZIDE (Reference) Method: Solvent Melting Method Carrier: PEG 6000 Before:40 % drug release/1 min After :100% drug release/1 min

Manufacturing Of Tablets Ingredient Role Justification Glicalazide 30 mg Main API (active pharmaceutical ingredient) Anti-diabitic action Calcium hydrogen phosphate dehydrate Enables improved granule fluidity and improved granule compressibility   Also slow down the dissolution kinetics . To control the dissolution profile of the active ingredient In the final blend • Compatible with API, Particle size needs control

Hydroxyl propyl methyl cellulose (HPMC) Matrix forming polymer Continue… Ingredient Role Justification Magnesium Sterate (0.25-4%) Lubricant • In the final blend. • Vegetable origin •Compatible with API • Particle size needs control Colloidal silica Flow agent Enhance flow property Compatible with API Hydroxyl propyl methyl cellulose (HPMC) Matrix forming polymer (5-20 %) Granulation purpose To control dissolution profile Particle size needs control Maltodextrine (0.25- 3 %) Enabling release of active ingredient that is perfectly prolonged and controlled Granulation

Evaluation Parameters Process Flow Process Control Particle size Density Particle shape Particle charge Proportion of material Nature of surface Surface area Chopper Mixing time Moisture content Evaluation Parameters Appearance Dissolution Assay Content uniformity LOD (Loss on Drying ) MIXING & GRANULATION Granulated mass mixed with HPMC Kneading during Binder addition Kneading at slow Speed after Binder addition Kneading at slow speed Blend uniformity

With colloidal Silica and magnesium stearate Lubrication With colloidal Silica and magnesium stearate Compression by rotary compression machine Blend Uniformity Particle Size Distribution Density Flowability/Compressibility blender type and time RPM of blender yield of lubricated granule mass Pre-compression force Main compression force Press speed Feeder speed/Type Ejection force Hopper design: Height and Vibration Hopper fill Assay Content Uniformity (whole and split) Weight Variation Hardness Friability Disintegration Usable Yield

In vitro Drug Release Study Dissolution parameter: Medium: 0.1N Hydrochloric acid followed by 6.8 Phosphate buffer Volume: 900ml Apparatus: USP-I (Basket) RPM: 50 rpm Temperature: 37°C ± 0.5°C Time 24 hrs Comparision with Market Preparation(Similarity study)

Stability Study Acelarated Stability syudy: Tablets stored for 3 months 40.2 oC and 75.5% RH. Carry out DSC for excipient compatibility Carry out in-vitro dissolution study and compare it with before 3 months results

Available Products in Regulated Marketed It is marketed as Glizid, Glyloc and Reclide in India & Diamicron in Canada. In the Philippines, Servier markets it as Diamicron MR Many generic equivalents are also available e.g. Glubitor-OD, Clizid. It is not marketed in the United States (US)

REFERECES : S. Biswal, ‘Enhancement of Dissolution Rate of Gliclazide Using Solid Dispersions with Polyethylene Glycol 6000’ AAPS PharmSciTech, Vol. 9, No. 2, June 2008 andre.raw@fda.hhs.gov Pharmainfo.net Wikipedia http://www.medicines.org.uk/EMC/default.aspx http://www.freepatentsonline.com/search.html